Display options
Cite
Ulivi P, Petracci E, Marisi G, et al. Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. J Clin Med. 2019;8(2)doi: 10.3390/jcm8020131.
Ulivi, P., Petracci, E., Marisi, G., Baglivo, S., Chiari, R., Billi, M., Canale, M., Pasini, L., Racanicchi, S., Vagheggini, A., Delmonte, A., Mariotti, M., Ludovini, V., Bonafè, M., Crinò, L., & Grignani, F. (2019). Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. Journal of clinical medicine, 8(2), . https://doi.org/10.3390/jcm8020131
Ulivi, Paola, et al. "Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer." Journal of clinical medicine vol. 8,2 (2019). doi: https://doi.org/10.3390/jcm8020131
Ulivi P, Petracci E, Marisi G, Baglivo S, Chiari R, Billi M, Canale M, Pasini L, Racanicchi S, Vagheggini A, Delmonte A, Mariotti M, Ludovini V, Bonafè M, Crinò L, Grignani F. Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. J Clin Med. 2019 Jan 23;8(2). doi: 10.3390/jcm8020131. PMID: 30678026; PMCID: PMC6407000.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2019 Jan 23;8(2). doi: 10.3390/jcm8020131.

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer.

Journal of clinical medicine

Paola Ulivi, Elisabetta Petracci, Giorgia Marisi, Sara Baglivo, Rita Chiari, Monia Billi, Matteo Canale, Luigi Pasini, Serena Racanicchi, Alessandro Vagheggini, Angelo Delmonte, Marita Mariotti, Vienna Ludovini, Massimiliano Bonafè, Lucio Crinò, Francesco Grignani

Affiliations

  1. Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  2. Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  3. Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  4. Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, 06129 Perugia, Italy. [email protected].
  5. Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, 06129 Perugia, Italy. [email protected].
  6. General Pathology Unit, Department of Medicine, University of Perugia, 06132 Perugia, Italy. [email protected].
  7. Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  8. Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  9. General Pathology Unit, Department of Medicine, University of Perugia, 06132 Perugia, Italy. [email protected].
  10. Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  11. Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  12. Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  13. Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, 06129 Perugia, Italy. [email protected].
  14. Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  15. Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. [email protected].
  16. General Pathology Unit, Department of Medicine, University of Perugia, 06132 Perugia, Italy. [email protected].

PMID: 30678026 PMCID: PMC6407000 DOI: 10.3390/jcm8020131

Abstract

Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related death worldwide, with a low 5-year survival rate even in fully resected early-stage disease. Novel biomarkers to identify patients at higher risk of relapse are needed. We studied the prognostic value of 84 circulating microRNAs (miRNAs) in 182 patients with resected early-stage NSCLC (99 adenocarcinoma (ADC), 83 squamous cell carcinoma (SCC)) from whom peripheral blood samples were collected pre-surgery. miRNA expression was analyzed in relation to disease-free survival (DFS) and overall survival (OS). In univariable analyses, five miRNAs (miR-26a-5p, miR-126-3p, miR-130b-3p, miR-205-5p, and miR-21-5p) were significantly associated with DFS in SCC, and four (miR-130b-3p, miR-26a-5p, miR-126-3p, and miR-205-5p) remained significantly associated with OS. In ADC, miR-222-3p, miR-22-3p, and mir-93-5p were significantly associated with DFS, miR-22-3p remaining significant for OS. Given the high-dimensionality of the dataset, multivariable models were obtained using a regularized Cox regression including all miRNAs and clinical covariates. After adjustment for disease stage, only miR-126-3p showed an independent prognostic role, with higher values associated with longer DFS in SCC patients. With regard to ADC and OS, no miRNA remained significant in multivariable analysis. Further investigation into the role of miR-126 as a prognostic marker in early-stage NSCLC is warranted.

Keywords: early-stage NSCLC; miRNAs; plasma; prognosis

References

  1. N Engl J Med. 2004 Jan 22;350(4):351-60 - PubMed
  2. N Engl J Med. 2004 Apr 22;350(17):1713-21 - PubMed
  3. Nature. 2005 Jun 9;435(7043):834-8 - PubMed
  4. N Engl J Med. 2005 Jun 23;352(25):2589-97 - PubMed
  5. Nat Rev Cancer. 2005 Nov;5(11):845-56 - PubMed
  6. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 - PubMed
  7. Nat Rev Cancer. 2006 Nov;6(11):857-66 - PubMed
  8. Cancer Cell. 2008 Jan;13(1):48-57 - PubMed
  9. Biochem Biophys Res Commun. 2008 Sep 5;373(4):607-12 - PubMed
  10. Arch Intern Med. 2008 Jul 28;168(14):1541-9 - PubMed
  11. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  12. Cancer Res. 2009 Jul 15;69(14):5776-83 - PubMed
  13. Annu Rev Med. 2009;60:167-79 - PubMed
  14. Carcinogenesis. 2009 Nov;30(11):1903-9 - PubMed
  15. Biochem Biophys Res Commun. 2010 Jan 15;391(3):1483-9 - PubMed
  16. J Clin Oncol. 2010 Apr 1;28(10):1721-6 - PubMed
  17. Cancer. 2011 Jul 15;117(14):3193-200 - PubMed
  18. Brief Bioinform. 2011 May;12(3):203-14 - PubMed
  19. Clin Cancer Res. 2011 Apr 1;17(7):1875-82 - PubMed
  20. Clin Biochem. 2012 May;45(7-8):575-81 - PubMed
  21. PLoS One. 2012;7(8):e42978 - PubMed
  22. PLoS One. 2013;8(1):e54596 - PubMed
  23. Lung Cancer. 2013 Sep;81(3):388-96 - PubMed
  24. Br J Cancer. 2014 Feb 18;110(4):991-1000 - PubMed
  25. PLoS One. 2014 Jul 08;9(7):e101899 - PubMed
  26. PLoS One. 2014 Jul 16;9(7):e101802 - PubMed
  27. Virchows Arch. 2014 Oct;465(4):463-71 - PubMed
  28. Int J Clin Exp Pathol. 2015 Nov 01;8(11):14983-8 - PubMed
  29. Onco Targets Ther. 2016 Apr 28;9:2547-55 - PubMed
  30. Clin Lung Cancer. 2016 Sep;17(5):e65-e75 - PubMed
  31. Oncotarget. 2016 Sep 13;7(37):59664-59675 - PubMed
  32. Onco Targets Ther. 2016 Sep 15;9:5679-5692 - PubMed
  33. World J Surg Oncol. 2016 Aug 24;14(1):224 - PubMed
  34. CA Cancer J Clin. 2017 Jan;67(1):7-30 - PubMed
  35. Cancer Cell Int. 2017 Jul 14;17:71 - PubMed
  36. Clin Pharmacol Ther. 2018 Jun;103(6):1061-1073 - PubMed
  37. Oncotarget. 2017 Jun 22;8(34):56143-56157 - PubMed
  38. Cancer Biomark. 2017 Sep 7;20(3):283-288 - PubMed
  39. J Thorac Dis. 2017 Oct;9(10):3735-3746 - PubMed
  40. Biom J. 2018 May;60(3):431-449 - PubMed
  41. Medicine (Baltimore). 2018 Jun;97(25):e10996 - PubMed
  42. J Cell Physiol. 2019 Jul;234(7):10918-10925 - PubMed

Publication Types